echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The Applications of 2-ETHYL-1,2,3,4-TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID

    The Applications of 2-ETHYL-1,2,3,4-TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID

    • Last Update: 2023-05-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    The Chemical Industry's Guide to 2-Ethyl-1,2,3,4-Tetrahydro-Isoquinoline-3-Carboxylic Acid

    In the world of chemistry, there are countless compounds with unique properties and potential applications.
    One such compound is 2-ethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid, commonly referred to as THIQ or 2-ethylTHIQ.
    This versatile compound has found applications in a variety of industries, including pharmaceuticals, agrochemicals, and cosmetics.


    Introduction to 2-Ethyl-1,2,3,4-Tetrahydro-Isoquinoline-3-Carboxylic Acid

    2-ethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid is a synthetic compound that belongs to the class of isoquinolines.
    It is a white to off-white solid with a melting point of 170-173°C and a density of 1.
    53 g/mL.
    The compound is slightly soluble in water but highly soluble in organic solvents such as ethanol and dichloromethane.


    The chemical structure of 2-ethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid consists of a six-membered benzene ring fused to a five-membered isoquinoline ring.
    The carbon atom in the benzene ring is substituted with two ethyl groups and a carboxylic acid group, making it a versatile building block for the synthesis of various molecules.


    Applications of 2-Ethyl-1,2,3,4-Tetrahydro-Isoquinoline-3-Carboxylic Acid in Pharmaceuticals

    2-ethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid has found utility in the pharmaceutical industry as an intermediate in the synthesis of various drugs.
    The compound can be used as a building block for the synthesis of anti-inflammatory drugs, analgesics, anti-depressants, and anti-cancer agents.
    For example, the compound can be hydrolyzed to yield 2-ethyl-1,2,3,4-tetrahydro-isoquinoline-1,2-dione, which can be further transformed into the antidepressant drug trazodone.


    In addition to its use as a precursor to other drugs, 2-ethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid has also been studied for its potential therapeutic effects in various animal models.
    For example, it has been shown to have anti-inflammatory and analgesic effects in models of pain and swelling, and it has also been studied for its potential to prevent the spread of cancer cells.


    Applications of 2-Ethyl-1,2,3,4-Tetrahydro-Isoquinoline-3-Carboxylic Acid in Agrochemicals

    2-ethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid has also found utility in the agrochemical industry as a herbicide.
    The compound has been shown to be effective in controlling the growth of various weeds, such as Johnston grass and lolium.


    The herbicidal activity of 2-ethyl-1,2,


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.